Baxter International Inc. (BAX) Earnings Call Transcripts

Baxter International Inc.'s Latest Earnings Call - September 9, 2026

In the Q2 2026 earnings call, Baxter International Inc. (BAX:US) reported a revenue growth of 5% operationally, prompting management to raise full-year guidance from flat to 2-3%. The company emphasized a focus on debt repayment and operational improvements, with CEO Andrew Hider expressing optimism about the future despite acknowledging ongoing challenges. Key metrics included an EPS of $0.50, which was inline with expectations, and a projected margin improvement in the second half of the year.

Reported metrics

Guidance from management

Baxter maintained its guidance for 2026, projecting 2-3% revenue growth, with a focus on operational improvements and debt repayment strategies.

What management said

So while I won't comment on the timing, and we will have 1 at some point, it's more around execution. And 1 of the reasons why we pulled it for earlier this year was because we wanted to build that credibility around high safety ratio around aligning the business for execution and what we set out to accomplish. And so there will be a point in time when we get there, we'll certainly notify and walk through the path fo...

So I'll start with this, and I want to put a caveat, no single quarter is going to define us. And I would say it was a decent quarter, and we're pleased with the progress we've made. And a lot of that stems around the tough decisions we made to get to where we are. So we're pleased with the progress, but we have a lot of work to do for the second half of the year. And so our teams, while we will certainly take the mo...

What analysts pressed on

Analysts raised concerns about the sustainability of growth in the infusion systems and injectables segments, questioning the timeline for recovery and the impact of supply chain challenges on future performance.

Main topics on the call

• Revenue Growth and Guidance Update — Baxter achieved a 5% operational growth in Q2 2026, leading to an increase in full-year guidance from flat to 2-3%. CEO Andrew Hider stated, "we're pleased with the progress we've made," highlighting the company's commit...
• Debt Repayment Strategy — Management reiterated a strong focus on reducing leverage, with a target to achieve net debt to EBITDA of under 3x by year-end. Hider noted, "debt repayment is real because we want to deploy capital," indicating a strate...
• Operational Improvements and Continuous Growth — Baxter launched the Growth and Performance System (GPS) to drive continuous improvement across the organization. Hider emphasized, "if you can measure it, you can manage it," showcasing a commitment to operational excell...
• Challenges in Infusion Systems and Injectables — Management acknowledged ongoing challenges in the infusion systems and injectables segments, citing supply chain issues. Hider mentioned, "we see a light at the end of the tunnel," indicating optimism for recovery in the...

Read the full Baxter International Inc. transcript (September 9, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 88 Baxter International Inc. earnings call transcripts on record, spanning January 13, 2020 to September 9, 2026. Based on this history, Baxter International Inc. reports quarterly. The most recent call on file is dated September 9, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

BAX

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Health Care Equipment and Supplies

Calls on record

88

First call

January 13, 2020

Most recent

September 9, 2026

Reporting cadence

quarterly